

## HOTLINE: Effective February 22, 2022

New Test 3004424 Biotinidase Deficiency (BTD) Sequencing BTD NGS



Additional Technical Information



Patient History for Biotinidase Deficiency (*BTD*) Testing

Methodology: Massively Parallel Sequencing

Performed: Varies Reported: 3 weeks

Specimen Required: Collect: Lavender (EDTA) or Yellow (ACD Solution A or B).

Specimen Preparation: Transport 3 mL whole blood. (Min: 3 mL)

Storage/Transport Temperature: Refrigerated.

Unacceptable Conditions: Serum or plasma; grossly hemolyzed or frozen specimens

Stability (collection to initiation of testing): Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

**Reference Interval:** By report

## **Interpretive Data:**

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

**Note:** Gene tested: *BTD* (NM\_001370658)

BTD (NM\_000060) exon 1 is not covered by sequencing.

**CPT Code(s):** 81404

New York DOH approval pending. Call for status update.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.